Paradigm Shift Is Needed in the Field of Pulmonary Arterial Hypertension for Its Entrance Into the Precision Medicine Era

Pulmonary arterial hypertension (PAH) is a complex disease leading to right ventricular (RV) failure and death, because of a proliferative vascular remodeling that obstructs the lumen of resistance pulmonary arteries (PA). Despite tremendous investments from the scientific community and industry over the past 20 years, the disease remains deadly. 1 Currently approved therapies act mainly as vasodilators that cannot reverse the disease or improve survival, while they are offered at a prohibitive cost for many patients. 1 Is the field in crisis?